Merck Serono and Ablynx sign third nano-antibody deal in osteoarthritis
This article was originally published in Scrip
Executive Summary
Ablynx of Belgium has entered a third collaboration with Merck Serono. It will discover and co-develop Nanobodies against two targets in osteoarthritis.